Syneron Medical (NASDAQ: ELOS) and NeuroMetrix (NASDAQ:NURO) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations.

Profitability

This table compares Syneron Medical and NeuroMetrix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Syneron Medical -1.09% -1.74% -1.30%
NeuroMetrix -83.92% -209.56% -135.03%

Insider and Institutional Ownership

69.2% of Syneron Medical shares are held by institutional investors. Comparatively, 6.5% of NeuroMetrix shares are held by institutional investors. 4.4% of NeuroMetrix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Syneron Medical and NeuroMetrix, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Syneron Medical 0 1 1 0 2.50
NeuroMetrix 0 0 2 0 3.00

Syneron Medical presently has a consensus target price of $11.00, indicating a potential upside of 0.00%. NeuroMetrix has a consensus target price of $26.00, indicating a potential upside of 1,161.52%. Given NeuroMetrix’s stronger consensus rating and higher probable upside, analysts clearly believe NeuroMetrix is more favorable than Syneron Medical.

Valuation & Earnings

This table compares Syneron Medical and NeuroMetrix’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Syneron Medical N/A N/A N/A ($0.12) -91.66
NeuroMetrix $15.72 million 0.28 -$13.27 million ($20.01) -0.10

Syneron Medical has higher revenue, but lower earnings than NeuroMetrix. Syneron Medical is trading at a lower price-to-earnings ratio than NeuroMetrix, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Syneron Medical has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, NeuroMetrix has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500.

Summary

Syneron Medical beats NeuroMetrix on 6 of the 11 factors compared between the two stocks.

Syneron Medical Company Profile

Syneron Medical Ltd. is engaged in the manufacture, research, development, marketing and sale of equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners. The Company’s aesthetic medical products are based on its various technologies, including Electro-Optical Synergy (ELOS) technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments. The Company’s products target a range of non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, tattoo removal, rejuvenation of the skin’s appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin, and laser-assisted lipolysis.

NeuroMetrix Company Profile

NeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.

Receive News & Ratings for Syneron Medical Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneron Medical Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.